Literature DB >> 33831473

Standardized pyrogen testing of medical products with bacterial endotoxin test (bet) as a substitute for rabbit Pyrogen testing (RPT): A scoping review.

Janaína Spoladore1, Izabela Gimenes1, Róber Bachinski2, Jesse P Negherbon3, Thomas Hartung4, José Mauro Granjeiro5, Gutemberg Gomes Alves6.   

Abstract

The Bacterial Endotoxin Test (BET) is a method for exclusion of endotoxin-related pyrogen contamination in pharmaceutical products, as an alternative to the Rabbit Pyrogen Test (RPT). However, BET does not detect a broad range of biologically relevant pyrogens, and interferences can limit its practical use for different medical products. This work aimed to scope the evidence in the scientific literature for case-by-case validity assessments of BET in different uses for medical products. A search strategy was conducted in PubMed, Scopus, and Web of Science in April 2020, according to the PRISMA-ScR statement. Twenty-two references were included, evaluating medical products for endotoxin contamination through both BET and RPT according to standardized protocols. A critical appraisal was performed through ToxRTool, followed by data extraction and qualitative synthesis of outcomes and methodological issues. Four classes of products assessed by BET were identified, including nanoparticles, drugs, blood and biological products. A considerable variation was observed on the BET methods used. Collectively, the evidence indicates different factors influencing the outcome of BET, including the chemical nature of samples that may cause interference depending on the selected method. While some applications to medical products appear adequate, others, such as nanoparticles, may require the use of different in vitro pyrogen testing methods, reinforcing the need for case-by-case validation for each BET method and type of medical product.
Copyright © 2021. Published by Elsevier Ltd.

Keywords:  Alternative methods; Bacterial endotoxin test; Medical products, pyrogens, rabbit Pyrogen test; Scoping review

Year:  2021        PMID: 33831473     DOI: 10.1016/j.tiv.2021.105160

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  1 in total

1.  Common deficiencies found in generic Finished Pharmaceutical Product (FPP) applications submitted for registration to the South African Health Products Regulatory Authority (SAHPRA).

Authors:  Lerato Moeti; Madira Litedu; Jacques Joubert
Journal:  J Pharm Policy Pract       Date:  2022-01-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.